Study Completed

Fever, Migraine, Pain

Bayer Identifier:

12011

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2006-002057-77

EU CT Number:

Not Available

BAY81-8781 Thrombocyte inhibition, pharmacokinetics

Trial purpose

Primary Objective:
To investigate the function of platelets after different single doses of
acetylsalicylic acid (ASA) given as intravenous (IV) BAY 81-8781 and
Aspirin® tablets in comparison to inactive intravenous (IV) treatment.

Secondary Objective:
To investigate safety, tolerability, and pharmacokinetics of these
treatments.

Key Participants Requirements

Sex

N/A

Age

40 - 58 Years

Trial summary

Enrollment Goal

Trial Dates

July 2006 - December 2006

Phase

Phase 1

Could I Receive a placebo

N/A

Products

Aspirin (Acetylsalicylic Acid, BAY81-8781)

Accepts Healthy Volunteer

N/A

Where to participate

Status	Institution	Location
Completed		Wuppertal, 42096, Germany

Trial design

Randomized, open-label, six-fold cross-over study to investigate the pharmacodynamic effect on thrombocytes and the safety, tolerability and pharmacokinetics of acetylsalicylic acid after single intravenous doses of BAY 81-8781 and oral doses of Aspirin plain tablets in 24 healthy male and female subjects

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

Randomized

Blinding

N/A

Assignment

Crossover Assignment

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.